Core Viewpoint - Addex Therapeutics has amended its At The Market Offering Agreement with H.C. Wainwright & Co. to allow for the sale of American Depositary Shares (ADSs) with an aggregate offering price of up to $3.3 million [1] Group 1: Offering Details - The amended ATM Agreement enables Addex to sell ADSs at its discretion through H.C. Wainwright & Co. [1] - H.C. Wainwright & Co. will sell the ADSs using methods permitted by law, including sales on The Nasdaq Capital Market [2] - The sales commission for H.C. Wainwright & Co. is set at three percent (3.0%) of the gross sales proceeds from any ADSs sold [2] Group 2: Company Background - Addex Therapeutics is focused on developing novel small molecule allosteric modulators for neurological disorders [5] - The lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [5] - Addex has partnerships for developing GABAB PAM drug candidates for substance use disorders and is advancing an independent GABAB PAM program for chronic cough [5] Group 3: Corporate Structure - Addex holds a 20% equity interest in Neurosterix US Holdings LLC, which is advancing allosteric modulator programs for various mental health disorders [5] - The company has also invested in Stalicla, a private Swiss company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders [5] Group 4: Stock Information - Addex shares are listed on the SIX Swiss Exchange and NASDAQ Capital Market under the ticker symbol "ADXN" [6]

Core Viewpoint - Snail, Inc. has entered into an At The Market Offering Agreement to sell up to $4,500,000 of its Class A Common Stock to support its digital asset initiative, including the potential introduction of a proprietary stablecoin backed by U.S. dollars [1][2]. Group 1: Offering Details - The Offering will be conducted under a Sales Agreement with H.C. Wainwright & Co. as the sales agent, allowing the company to sell shares from time to time in an at the market offering [1][3]. - The shares will be sold through methods permitted by law, including direct sales on the Nasdaq Capital Market [3]. - The Offering will be made only by means of a prospectus supplement filed with the SEC, which is part of the company's shelf registration statement [4]. Group 2: Use of Proceeds - The net proceeds from the sale of the shares will primarily be used for working capital to support the company's digital asset initiative, including the evaluation of a proprietary stablecoin [2]. Group 3: Company Overview - Snail, Inc. is a leading global independent developer and publisher of interactive digital entertainment, with a portfolio of premium games for various platforms [6].